🇺🇸 FDA
Patent

US 11478511

Lymphocyte biomarkers for determining the clinical response to cell therapy

granted A61KA61K2239/31A61K2239/38

Quick answer

US patent 11478511 (Lymphocyte biomarkers for determining the clinical response to cell therapy) held by Takeda Pharmaceutical Company Limited expires Mon Oct 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Takeda Pharmaceutical Company Limited
Grant date
Tue Oct 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K2239/31, A61K2239/38, A61K35/28, A61K35/33